

## **Global Oncology Based In-Vivo CRO Market Report and Forecast 2023-2031**

Market Report | 2023-07-13 | 140 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Oncology Based In-Vivo CRO Market Report and Forecast 2023-2031

Global Oncology Based In-Vivo CRO Market Outlook

The global oncology based in-vivo CRO market attained a value of USD 1.1 billion in 2022, driven by increasing focus on cancer research and development of novel oncology therapeutics. The market is expected to grow at a CAGR of 7.87% during the forecast period of 2023-2031 to attain a value of USD 2.2 billion by 2031.

Oncology Based In-Vivo CRO: Introduction

Oncology-based in-vivo Contract Research Organization (CRO) refers to a specialized service provider that conducts preclinical and clinical research studies specifically focused on oncology (cancer) therapeutics and treatments. These CROs offer a range of services to support the development and evaluation of anti-cancer drugs or therapies.

The uses of oncology-based in-vivo CRO services include:

- Preclinical Research: Oncology-based in-vivo CROs conduct preclinical studies using animal models to evaluate the safety, efficacy, and pharmacokinetics of potential cancer treatments. These studies provide crucial data on drug candidates' effectiveness, toxicity, and potential side effects before they progress to human trials.
- Tumor Xenograft Models: In-vivo CROs specialize in creating tumor xenograft models, where human tumor cells are implanted into animals to mimic the growth and behavior of tumors in humans. These models are used to evaluate the anti-tumor activity of drug candidates and assess their potential as cancer therapies.
- Pharmacokinetic and Toxicity Studies: Oncology-based in-vivo CROs perform pharmacokinetic studies to assess how a drug is absorbed, distributed, metabolized, and eliminated in the body. They also conduct toxicity studies to evaluate the safety and potential adverse effects of drug candidates on living organisms.
- Efficacy and Mechanism of Action Studies: These CROs design and execute studies to evaluate the efficacy of anti-cancer drugs, assessing their ability to inhibit tumor growth, induce cell death, or target specific molecular pathways involved in cancer progression. They also investigate the mechanisms of action of these drugs to understand their mode of activity at a molecular

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

level.

-□Clinical Research Support: In addition to preclinical studies, oncology-based in-vivo CROs may provide clinical research services, assisting pharmaceutical companies in conducting early-phase clinical trials to assess the safety, tolerability, and preliminary efficacy of cancer therapies in human subjects.

The benefits of oncology-based in-vivo CRO services include:

-□Expertise and Specialization: These CROs possess specialized knowledge and expertise in oncology research, allowing them to design and execute studies specific to cancer therapeutics. Their focused approach ensures high-quality research and reliable results.

-□Cost and Time Efficiency: Outsourcing oncology research to in-vivo CROs can be more cost-effective and time-efficient than conducting studies in-house. CROs have established infrastructure, animal models, and protocols, reducing the need for companies to invest in their own research facilities and resources.

-□Compliance and Regulatory Support: Oncology-based in-vivo CROs are experienced in working within regulatory guidelines and ensuring compliance with ethical standards and animal welfare regulations. They provide support in meeting regulatory requirements and obtaining necessary approvals for preclinical and clinical studies.

-□Data Quality and Interpretation: CROs employ skilled scientists and researchers who can generate high-quality data and provide comprehensive analysis and interpretation of research results. This aids in informed decision-making during drug development and helps pharmaceutical companies advance promising candidates.

-□Risk Mitigation: Collaboration with oncology-based in-vivo CROs can help mitigate risks associated with drug development. Their expertise in study design, execution, and data analysis assists in identifying potential issues and optimizing study protocols, reducing the likelihood of costly failures in later stages of drug development.

Overall, oncology-based in-vivo CROs play a crucial role in supporting the development of novel cancer therapies by providing specialized research services, expertise, and infrastructure necessary for preclinical and clinical evaluation of potential anti-cancer drugs.

#### ONCOLOGY BASED IN-VIVO CRO Market Segmentations

The market can be categorised into indication, model, and region.

##### Market Breakup by Indication

-□Blood Cancer

-□Solid Tumour

-□Other Indications

##### Market Breakup by Model

-□Syngeneic

-□Xenograft

-□Patient Derived Xenograft (PDX)

##### Market Breakup by Region

-□North America

-□Europe

-□Asia Pacific

-□Latin America

-□Middle East and Africa

#### Oncology Based In-Vivo CRO Market Overview

The oncology-based in-vivo Contract Research Organization (CRO) market has witnessed significant growth and is projected to continue expanding in the coming years. Several factors contribute to the positive market scenario.

One of the primary drivers of market growth is the increasing focus on cancer research and the development of novel oncology therapeutics. The rising prevalence of cancer worldwide and the urgent need for effective treatments drive the demand for specialized research services provided by oncology-based in-vivo CROs. Pharmaceutical companies and biotechnology firms rely on these CROs to conduct preclinical and clinical studies specific to oncology, facilitating the development and evaluation of potential cancer therapies.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Moreover, the complexity of oncology research and the need for specialized expertise and infrastructure have led to an increased outsourcing of oncology studies to in-vivo CROs. These CROs possess the necessary facilities, animal models, and experienced researchers to perform preclinical studies using tumour xenograft models, evaluate drug efficacy and safety, and provide valuable insights into the pharmacokinetics and mechanisms of action of anti-cancer drugs.

In conclusion, the oncology-based in-vivo CRO market is expected to witness continued growth due to the increasing demand for specialized oncology research services, advancements in imaging technologies, collaborations between pharmaceutical companies and CROs, and the rising focus on developing effective cancer therapeutics. As the field of oncology research continues to advance, the need for specialized in-vivo CRO services will remain significant. Continued investment in research and development, technological innovations, and strategic collaborations will shape the future of the oncology-based in-vivo CRO market.

#### Key players in the global Oncology Based In-Vivo CRO Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the oncology based in-vivo CRO market are as follows:

- [ ] Crown Bioscience Inc.
- [ ] Charles River Laboratories Inc.
- [ ] ICON PLC
- [ ] Taconic Biosciences Inc.
- [ ] Covance Inc.
- [ ] Eurofins Scientific
- [ ] EVOTEC
- [ ] The Jackson Laboratory
- [ ] Wuxi AppTec.
- [ ] MI Bioresearch Inc.

\*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

#### **Table of Contents:**

- 1 [ ] Preface
- 1.1 [ ] Objectives of the Study
- 1.2 [ ] Key Assumptions
- 1.3 [ ] Report Coverage - Key Segmentation and Scope
- 1.4 [ ] Research Methodology
- 2 [ ] Executive Summary
- 3 [ ] Global Oncology Based In-Vivo Cro Market Overview
- 3.1 [ ] Global Oncology Based In-Vivo Cro Market Historical Value (2016-2022)
- 3.2 [ ] Global Oncology Based In-Vivo Cro Market Forecast Value (2023-2031)
- 4 [ ] Global Oncology Based In-Vivo Cro Market Dynamics
- 4.1 [ ] Market Drivers and Constraints
- 4.2 [ ] SWOT Analysis
- 4.3 [ ] Porter's Five Forces Model
- 4.4 [ ] Key Demand Indicators
- 4.5 [ ] Key Price Indicators

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.6 Industry Events, Initiatives, and Trends
- 4.7 Value Chain Analysis
- 5 Global Oncology Based In-Vivo Cro Market Segmentation
  - 5.1 Global Oncology Based In-Vivo Cro Market by Indication
    - 5.1.1 Market Overview
    - 5.1.2 Blood Cancer
    - 5.1.3 Solid Tumors
    - 5.1.4 Other Indications
  - 5.2 Global Oncology Based In-Vivo Cro Market by Model
    - 5.2.1 Market Overview
    - 5.2.2 Syngeneic
    - 5.2.3 Xenograft
    - 5.2.4 Patient Derived Xenograft (PDX)
  - 5.3 Global Oncology Based In-Vivo Cro Market by Region
    - 5.3.1 Market Overview
    - 5.3.2 North America
    - 5.3.3 Europe
    - 5.3.4 Asia Pacific
    - 5.3.5 Latin America
    - 5.3.6 Middle East and Africa
- 6 North America Oncology Based In-Vivo Cro Market
  - 6.1 Market Share by Country
  - 6.2 United States of America
  - 6.3 Canada
- 7 Europe Oncology Based In-Vivo Cro Market
  - 7.1 Market Share by Country
  - 7.2 United Kingdom
  - 7.3 Germany
  - 7.4 France
  - 7.5 Italy
  - 7.6 Others
- 8 Asia Pacific Oncology Based In-Vivo Cro Market
  - 8.1 Market Share by Country
  - 8.2 China
  - 8.3 Japan
  - 8.4 India
  - 8.5 ASEAN
  - 8.6 Australia
  - 8.7 Others
- 9 Latin America Oncology Based In-Vivo Cro Market
  - 9.1 Market Share by Country
  - 9.2 Brazil
  - 9.3 Argentina
  - 9.4 Mexico
  - 9.5 Others
- 10 Middle East and Africa Oncology Based In-Vivo Cro Market
  - 10.1 Market Share by Country

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.2 Saudi Arabia
- 10.3 United Arab Emirates
- 10.4 Nigeria
- 10.5 South Africa
- 10.6 Others
- 11 Regulatory Framework
  - 11.1 Regulatory Overview
    - 11.1.1 US FDA
    - 11.1.2 EU EMA
    - 11.1.3 INDIA CDSCO
    - 11.1.4 JAPAN PMDA
    - 11.1.5 Others
- 12 Patent Analysis
  - 12.1 Analysis by Type of Patent
  - 12.2 Analysis by Publication year
  - 12.3 Analysis by Issuing Authority
  - 12.4 Analysis by Patent Age
  - 12.5 Analysis by CPC Analysis
  - 12.6 Analysis by Patent Valuation
  - 12.7 Analysis by Key Players
- 13 Grants Analysis
  - 13.1 Analysis by year
  - 13.2 Analysis by Amount Awarded
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Grant Application
  - 13.5 Analysis by Funding Institute
  - 13.6 Analysis by NIH Departments
  - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
  - 14.1 Analysis by Trial Registration Year
  - 14.2 Analysis by Trial Status
  - 14.3 Analysis by Trial Phase
  - 14.4 Analysis by Therapeutic Area
  - 14.5 Analysis by Geography
- 15 Funding and Investment Analysis
  - 15.1 Analysis by Funding Instances
  - 15.2 Analysis by Type of Funding
  - 15.3 Analysis by Funding Amount
  - 15.4 Analysis by Leading Players
  - 15.5 Analysis by Leading Investors
  - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
  - 16.1 Analysis by Partnership Instances
  - 16.2 Analysis by Type of Partnership
  - 16.3 Analysis by Leading Players
  - 16.4 Analysis by Geography
- 17 Supplier Landscape

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.1□ Crown Bioscience Inc.
  - 17.1.1□ Financial Analysis
  - 17.1.2□ Product Portfolio
  - 17.1.3□ Demographic Reach and Achievements
  - 17.1.4□ Mergers and Acquisitions
  - 17.1.5□ Certifications
- 17.2□ Charles River Laboratories Inc.
  - 17.2.1□ Financial Analysis
  - 17.2.2□ Product Portfolio
  - 17.2.3□ Demographic Reach and Achievements
  - 17.2.4□ Mergers and Acquisitions
  - 17.2.5□ Certifications
- 17.3□ ICON PLC
  - 17.3.1□ Financial Analysis
  - 17.3.2□ Product Portfolio
  - 17.3.3□ Demographic Reach and Achievements
  - 17.3.4□ Mergers and Acquisitions
  - 17.3.5□ Certifications
- 17.4□ Taconic Biosciences Inc.
  - 17.4.1□ Financial Analysis
  - 17.4.2□ Product Portfolio
  - 17.4.3□ Demographic Reach and Achievements
  - 17.4.4□ Mergers and Acquisitions
  - 17.4.5□ Certifications
- 17.5□ Covance Inc.
  - 17.5.1□ Financial Analysis
  - 17.5.2□ Product Portfolio
  - 17.5.3□ Demographic Reach and Achievements
  - 17.5.4□ Mergers and Acquisitions
  - 17.5.5□ Certifications
- 17.6□ Eurofins Scientific
  - 17.6.1□ Financial Analysis
  - 17.6.2□ Product Portfolio
  - 17.6.3□ Demographic Reach and Achievements
  - 17.6.4□ Mergers and Acquisitions
  - 17.6.5□ Certifications
- 17.7□ EVOTEC
  - 17.7.1□ Financial Analysis
  - 17.7.2□ Product Portfolio
  - 17.7.3□ Demographic Reach and Achievements
  - 17.7.4□ Mergers and Acquisitions
  - 17.7.5□ Certifications
- 17.8□ The Jackson Laboratory
  - 17.8.1□ Financial Analysis
  - 17.8.2□ Product Portfolio
  - 17.8.3□ Demographic Reach and Achievements
  - 17.8.4□ Mergers and Acquisitions

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.8.5☐Certifications
- 17.9☐Wuxi AppTec.
- 17.9.1☐Financial Analysis
- 17.9.2☐Product Portfolio
- 17.9.3☐Demographic Reach and Achievements
- 17.9.4☐Mergers and Acquisitions
- 17.9.5☐Certifications
- 17.10☐MI Bioresearch Inc.
- 17.10.1☐Financial Analysis
- 17.10.2☐Product Portfolio
- 17.10.3☐Demographic Reach and Achievements
- 17.10.4☐Mergers and Acquisitions
- 17.10.5☐Certifications

- 18☐Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19☐Company Competitiveness Analysis (Additional Insight)
- 19.1☐Very Small Companies
- 19.2☐Small Companies
- 19.3☐Mid-Sized Companies
- 19.4☐Large Companies
- 19.5☐Very Large Companies
- 20☐Payment Methods (Additional Insight)
- 20.1☐Government Funded
- 20.2☐Private Insurance
- 20.3☐Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Global Oncology Based In-Vivo CRO Market Report and Forecast 2023-2031**

Market Report | 2023-07-13 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com